Dive Brief:
- Novo Nordisk has expanded its agreement with Amalgam Rx to support the commercialization of digital insulin initiation and titration app Dose Check.
- Amalgam Rx developed the app to help people with type 2 diabetes use basal insulin. The app enables users to wirelessly transmit blood glucose data from Bluetooth connected glucometers, view their dosing plan and record their insulin doses.
- Supported by Novo Nordisk, Amalgam Rx will integrate with connected insulin delivery devices, continuous glucose monitors and electronic health records.
Dive Insight:
Dose Check is designed to address the difficulties people with type 2 diabetes can face when they start on basal insulin. Research shows fear of hypoglycemia, burdensome regimens and anxiety can delay the initiation of basal insulin, as well as slow the adjustment and intensification of dosing. Another study found more than 70% of patients have no recollection of discussing dose titration with their healthcare professional.
Amalgam Rx thinks a mobile app, Dose Check, can make it easier for patients to start basal insulin. Novo Nordisk, a leading insulin provider, sees potential in the technology, leading it to expand its alliance with Amalgam Rx and invest in the company to support the commercialization of Dose Check.
“We’re expanding Dose Check’s geographic footprint and simplifying the way people living with diabetes and their clinicians access digital health solutions. We are now investing further in our partnership with Amalgam with the ambition to use innovative digital health solutions to further improve personalized care for people living with diabetes,” Thomas Thestrup-Terp, corporate vice president for digital strategy and solutions at Novo Nordisk, said in a statement.
Initially, Novo Nordisk worked with Amalgam Rx to commercialize Dose Check, a rebranded version of iSage Rx, in certain South American markets. The receipt of a CE mark for iSage Rx and Dose Check led Novo Nordisk to embark on a global expansion spanning multiple countries in Europe and Asia last year.
